{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T18:50:18Z","timestamp":1792349418495,"version":"4.4.0"},"reference-count":41,"publisher":"Informa UK Limited","issue":"1","funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2024,1,2]]},"DOI":"10.1080\/14728214.2024.2304059","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T12:32:30Z","timestamp":1704803550000},"page":"35-43","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["How promising are the latest monoclonal antibodies targeting amyloid-\u03b2 for the treatment of early Alzheimer\u2019s disease?"],"prefix":"10.1080","volume":"29","author":[{"given":"Jordan","family":"Beveridge","sequence":"first","affiliation":[{"name":"Saint Louis University School of Medicine, Department of Psychiatry and Behavioral Neuroscience, Division of Geriatric Psychiatry, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Kaniecki","sequence":"additional","affiliation":[{"name":"Saint Louis University School of Medicine, Department of Psychiatry and Behavioral Neuroscience, Division of Geriatric Psychiatry, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniketh","family":"Naidu","sequence":"additional","affiliation":[{"name":"Saint Louis University School of Medicine, Department of Psychiatry and Behavioral Neuroscience, Division of Geriatric Psychiatry, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bret David","family":"Silverglate","sequence":"additional","affiliation":[{"name":"Saint Louis University School of Medicine, Department of Psychiatry and Behavioral Neuroscience, Division of Geriatric Psychiatry, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Grossberg","sequence":"additional","affiliation":[{"name":"Saint Louis University School of Medicine, Department of Psychiatry and Behavioral Neuroscience, Division of Geriatric Psychiatry, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.1.452"},{"key":"e_1_3_4_4_1","unstructured":"Kumar A Tsao JW Alzheimer disease [internet]. Nih.Gov. StatPearls Publishing. 2019 [cited 2023 Sep 27]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK499922\/"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101777"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2850"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.335832"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071702"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-022-02454-z"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.4622"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4161"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211050405"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-022-00949-8"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.4607"},{"key":"e_1_3_4_16_1","unstructured":"CMS. CMS finalizes medicare coverage policy for monoclonal antibodies directed against amyloid for the treatment of Alzheimer\u2019s disease [internet]. Cms.Gov. CMS; 2023. [cited 2023 Aug 18]. Available from: https:\/\/www.cms.gov\/newsroom\/press-releases\/cms-finalizes-medicare-coverage-policy-mon%20oclonal-antibodies-directed-against-amyloid-treatment"},{"key":"e_1_3_4_17_1","unstructured":"EMA. Aduhelm: withdrawn application - European medicines agency [internet]. European Medicines Agency. European Medicines Agency. 2022. [cited 2023 Aug 18]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/withdrawn-applications\/aduhelm"},{"key":"e_1_3_4_18_1","unstructured":"National Library of Medicine. NCT05310071 [Internet]. Clinicaltrials.Gov. 2023 [cited 2023 Dec 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05310071"},{"key":"e_1_3_4_19_1","unstructured":"FDA. Highlights of prescribing information [internet]. 2022 [cited 2023 Aug 18]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761178s005lbl.pdf"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2021.41"},{"key":"e_1_3_4_21_1","unstructured":"FDA. FDA grants accelerated approval for Alzheimer\u2019s disease treatment [internet]. FDA. FDA; 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-disease-treatment"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p1580"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_4_24_1","unstructured":"Practical Neurology. VA will cover lecanemab for Alzheimer disease [internet]. Practical Neurology. 2023. [cited 2023 Aug 18]. Available from: https:\/\/practicalneurology.com\/news\/va-will-cover-lecanemab-for-alzheimer-disease"},{"key":"e_1_3_4_25_1","unstructured":"FDA. HIGHLIGHTS of PRESCRIBING INFORMATION [Internet]. 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761269s000lbl.pdf"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12112"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2021.56"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_3_4_31_1","unstructured":"ALZForum. Donanemab | ALZFORUM [Internet]. https:\/\/www.alzforum.org. 2023. Available from: https:\/\/www.alzforum.org\/therapeutics\/donanemab."},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2793"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.3392"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203040"},{"key":"e_1_3_4_36_1","unstructured":"Rogers MB Donanemab Mops Up Plaque Faster Than Aduhelm | ALZFORUM [Internet]. http:\/\/www.alzforum.org. 2022 [cited 2023 Aug 18]. Available from: https:\/\/www.alzforum.org\/news\/conference-coverage\/donanemab-mops-plaque-faster-aduhelm"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00197-8"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2019.06.005"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12388"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001190.pub3"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.14443"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.0315"},{"key":"e_1_3_4_43_1","unstructured":"National Library of Medicine. A study to test the efficacy safety and tolerability of bepranemab (UCB0107) in patients with mild cognitive impairment or mild Alzheimer\u2019s disease (AD) [Internet].\u00a0https:\/\/www.clinicaltrials.gov. 2023 [cited 2023 Dec 28]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04867616."}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2024.2304059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T16:56:59Z","timestamp":1727197019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2024.2304059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,2]]}},"alternative-id":["10.1080\/14728214.2024.2304059"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2024.2304059","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}